Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
Add more filters










Publication year range
1.
Acta Clin Belg ; 77(1): 233-240, 2022 Feb.
Article in English | MEDLINE | ID: mdl-32936748

ABSTRACT

A better understanding of disease pathology, improvements in relevant disease outcomes, better treatment strategies and the development of novel therapies all contribute to improving healthcare and treatment options. However, the global drug development model today is under increasing pressure, with very high drug development costs. Collaborative research is critical for bringing together different capabilities and expertise to increase the success of drug development, and large-scale collaborations with multiple partners are becoming increasingly common. Research clusters supported by local governments play an important role in bringing together academic centres, hospitals, scientists, and pharmaceutical and biotechnology industries. The 'triple helix' model, with academia, industry and governments working together, has been an important factor in the successful development of novel therapies. During the past 20 years, Galapagos has worked closely with academic centres, hospitals, governments and pharmaceutical companies to conduct innovative research and to develop a novel therapy for rheumatoid arthritis. These collaborations have brought unique knowledge, expertise and skills together, as well as crucial funding at various stages. Local governments in the Benelux have operated in this triple helix model to provide the necessary environment and to stimulate companies to achieve innovation through collaboration. Although the triple helix has already proved successful, evolution to a quadruple helix that includes patients and patient representatives could be the next step to ensure innovation remains transformational.


Subject(s)
Delivery of Health Care , Humans
2.
Ann Rheum Dis ; 72(5): 741-4, 2013 May.
Article in English | MEDLINE | ID: mdl-23161899

ABSTRACT

BACKGROUND: Mitogen-activated protein (MAP) kinases are key regulators of cytokine production, and are therefore potential targets for treatment of rheumatoid arthritis (RA). OBJECTIVE: This two-part phase II study investigated the efficacy and safety of a once-daily 50 mg GLPG0259 (an inhibitor of MAP kinase-activated protein kinase 5) dose vs placebo (part A). An interim analysis after part A would determine whether the dose-finding part (part B) would be performed. METHODS: In part A, eligible methotrexate (MTX)-refractory patients with RA were randomised to receive either a once-daily 50 mg dose of GLPG0259 or placebo, in addition to a stable dose of MTX, for 12 weeks. The primary efficacy end point was the percentage of patients achieving an American College of Rheumatology 20% improvement (ACR20) response after 12 weeks. RESULTS: The interim analysis showed no difference between the percentage of subjects achieving the primary efficacy variable of ACR20 or the secondary efficacy variables (ACR50, ACR70 and Disease Activity Score 28) at week 12 in the GLPG0259-treated (n=19) and placebo-treated (n=11) groups. Owing to lack of efficacy, the study was terminated, and part B was not initiated. CONCLUSIONS: This innovative study design quickly provided conclusive results on the lack of efficacy of GLPG0259 in patients with RA.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Protein Kinase Inhibitors/administration & dosage , Protein Serine-Threonine Kinases/antagonists & inhibitors , Administration, Oral , Adult , Aged , Antirheumatic Agents/administration & dosage , Arthritis, Rheumatoid/metabolism , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Intracellular Signaling Peptides and Proteins/metabolism , Male , Methotrexate/administration & dosage , Middle Aged , Placebos , Protein Kinase Inhibitors/adverse effects , Protein Serine-Threonine Kinases/metabolism , Treatment Failure
3.
Drugs R D ; 12(3): 141-63, 2012 Sep 01.
Article in English | MEDLINE | ID: mdl-22950522

ABSTRACT

BACKGROUND AND OBJECTIVES: GLPG0259 is a small-molecule inhibitor of mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5), a kinase enzyme that plays a role in important inflammatory pathways. The main objectives of the phase I clinical studies in early development were to characterize the pharmacokinetics, tolerability, and safety of GLPG0259 in healthy subjects, including the development of a solid dosage form (free-base pellets and fumarate salt capsules) and the potential for interaction of GLPG0259 with methotrexate. SUBJECTS AND METHODS: Four phase I studies were initiated. Study 1 was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses (1.5-150 mg) and multiple oral doses (20 and 50 mg once daily) of GLPG0259 in healthy male subjects (n = 34). Study 2 was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of oral multiple ascending doses of GLPG0259 (25-75 mg once daily) given for 14 days to healthy male subjects, and to get preliminary information on the potential pharmacokinetic interaction between GLPG0259 and methotrexate (n = 24). Studies 3 and 4 were open-label, randomized, crossover studies to compare the oral bioavailability of two solid dosage forms of GLPG0259 (a capsule) relative to an oral solution after a 100 mg or 50 mg single dose and to evaluate the effect of food on these formulations (n = 12 for each study). MAIN OUTCOME MEASURES: The non-compartmental pharmacokinetic parameters for plasma concentrations of GLPG0259 were determined, and a population pharmacokinetic model of GLPG0259 was developed to support the planning of the number and timing of the sparse samples to be taken per patient in the phase II study. Safety and tolerability data are also summarized. RESULTS: The absorption of GLPG0259 was slow, with a decrease in the absorption rate with increasing dose, and there was decreased elimination, with an apparent terminal elimination half-life of 26.0 hours. On the basis of statistical analysis of variance, the exposure to GLPG0259 increased in proportion to the dose over a 30-150 mg single-dose range and a 25-75 mg repeated-dose range. Between- and within-subject variability in GLPG0259 pharmacokinetics was low/moderate (coefficient of variation [CV] 16-30%). After once-daily repeated dosing, steady-state plasma concentrations were reached at between 5 and 8 dosing days, which is consistent with the long apparent elimination half-life of GLPG0259. Food increased the bioavailability of GLPG0259 given in a solid dosage form. Co-administration of GLPG0259 with a single dose of methotrexate 7.5 mg did not result in any change in the pharmacokinetic profiles of either GLPG0259 or methotrexate. CONCLUSION: In summary, the investigation of safety/tolerability and pharmacokinetics in the early development phase showed that single and repeated doses of GLPG0259 were safe and well tolerated. The most common adverse event reported was mild gastrointestinal discomfort. The pharmacokinetics characterized in healthy male subjects showed no major obstacles and supports a once-daily oral regimen in patients.


Subject(s)
Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacokinetics , Protein Serine-Threonine Kinases/antagonists & inhibitors , Administration, Oral , Adolescent , Adult , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Drug Interactions , Food-Drug Interactions , Humans , Male , Methotrexate/administration & dosage , Middle Aged , Protein Kinase Inhibitors/adverse effects , Young Adult
4.
Bioorg Med Chem Lett ; 20(14): 4004-11, 2010 Jul 15.
Article in English | MEDLINE | ID: mdl-20541405

ABSTRACT

Novel NS3/4A protease inhibitors comprising quinazoline derivatives as P2 substituent were synthesized. High potency inhibitors displaying advantageous PK properties have been obtained through the optimization of quinazoline P2 substituents in three series exhibiting macrocyclic P2 cyclopentane dicarboxylic acid and P2 proline urea motifs. For the quinazoline moiety it was found that 8-methyl substitution in the P2 cyclopentane dicarboxylic acid series improved on the metabolic stability in human liver microsomes. By comparison, the proline urea series displayed advantageous Caco-2 permeability over the cyclopentane series. Pharmacokinetic properties in vivo were assessed in rat on selected compounds, where excellent exposure and liver-to-plasma ratios were demonstrated for a member of the 14-membered quinazoline substituted P2 proline urea series.


Subject(s)
Carrier Proteins/antagonists & inhibitors , Hepacivirus/enzymology , Protease Inhibitors/chemical synthesis , Quinazolines/chemical synthesis , Viral Nonstructural Proteins/antagonists & inhibitors , Viral Proteins/antagonists & inhibitors , Area Under Curve , Caco-2 Cells , Humans , Intracellular Signaling Peptides and Proteins , Microsomes, Liver/metabolism , Protease Inhibitors/chemistry , Protease Inhibitors/pharmacokinetics , Protease Inhibitors/pharmacology , Quinazolines/chemistry , Quinazolines/pharmacokinetics , Quinazolines/pharmacology , Structure-Activity Relationship
5.
Eur J Pharm Biopharm ; 72(3): 502-8, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19328850

ABSTRACT

Long-acting parenteral formulations of antiretrovirals could facilitate maintenance and prophylactic treatment in HIV. Using the poorly water- and oil-soluble non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) as base or hydrochloride (HCl), nanosuspensions were prepared by wet milling (Elan NanoCrystal technology) in an aqueous carrier. Laser diffraction showed that the average particles size were (1) close to the targeted size proportionality (200-400-800 nm), with increasing distributions the larger the average particle size, and (2) were stable over 6 months. Following single-dose administration, the plasma concentration profiles showed sustained release of TMC278 over 3 months in dogs and 3 weeks in mice. On comparison of intramuscular and subcutaneous injection of 5mg/kg (200 nm) in dogs, the subcutaneous route resulted in the most stable plasma levels (constant at 25 ng/mL for 20 days, after which levels declined slowly to 1-3 ng/mL at 3 months); 200 nm nanosuspensions achieved higher and less variable plasma concentration profiles than 400 and 800 nm nanosuspensions. In mice, the pharmacokinetic profiles after a single 20mg/kg dose (200 nm) were similar with two different surfactants used (poloxamer 338, or d-alpha-tocopheryl polyethylene glycol 1000 succinate). In conclusion, this study provides proof-of-concept that 200-nm sized TMC278 nanosuspensions may act as long-acting injectable.


Subject(s)
HIV Infections/drug therapy , HIV-1/drug effects , Nanoparticles/administration & dosage , Nitriles/administration & dosage , Pyrimidines/administration & dosage , Animals , Chemistry, Pharmaceutical , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/chemical synthesis , Delayed-Action Preparations/pharmacokinetics , Dogs , Female , HIV Infections/virology , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/enzymology , HIV-1/growth & development , Injections, Intramuscular , Injections, Subcutaneous , Male , Mice , Nanoparticles/chemistry , Nitriles/chemical synthesis , Nitriles/pharmacokinetics , Pyrimidines/chemical synthesis , Pyrimidines/pharmacokinetics , Rilpivirine
6.
Antimicrob Agents Chemother ; 53(4): 1377-85, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19171797

ABSTRACT

The hepatitis C virus (HCV) NS3/4A serine protease has been explored as a target for the inhibition of viral replication in preclinical models and in HCV-infected patients. TMC435350 is a highly specific and potent inhibitor of NS3/4A protease selected from a series of novel macrocyclic inhibitors. In biochemical assays using NS3/4A proteases of genotypes 1a and 1b, inhibition constants of 0.5 and 0.4 nM, respectively, were determined. TMC435350 inhibited HCV replication in a cellular assay (subgenomic 1b replicon) with a half-maximal effective concentration (EC(50)) of 8 nM and a selectivity index of 5,875. The compound was synergistic with alpha interferon and an NS5B inhibitor in the replicon model and additive with ribavirin. In rats, TMC435350 was extensively distributed to the liver and intestinal tract (tissue/plasma area under the concentration-time curve ratios of >35), and the absolute bioavailability was 44% after a single oral administration. Compound concentrations detected in both plasma and liver at 8 h postdosing were above the EC(99) value measured in the replicon. In conclusion, given the selective and potent in vitro anti-HCV activity, the potential for combination with other anti-HCV agents, and the favorable pharmacokinetic profile, TMC435350 has been selected for clinical development.


Subject(s)
Antiviral Agents/pharmacology , Hepacivirus/drug effects , Heterocyclic Compounds, 3-Ring/pharmacology , Sulfonamides/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Animals , Drug Therapy, Combination , Heterocyclic Compounds, 3-Ring/administration & dosage , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Humans , Interferon-alpha/administration & dosage , Male , Protein Binding , Rats , Rats, Sprague-Dawley , Simeprevir , Sulfonamides/administration & dosage , Sulfonamides/pharmacokinetics , Tissue Distribution , Virus Replication/drug effects
7.
Bioorg Med Chem Lett ; 18(23): 6189-93, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-18954982

ABSTRACT

A novel series of P3-truncated macrocyclic HCV NS3/4A protease inhibitors containing a P2 proline-urea or carbamate scaffold was synthesized. Very potent inhibitors were obtained through the optimization of the macrocycle size, urea and proline substitution, and bioisosteric replacement of the P1 carboxylic acid moiety. Variation of the lipophilicity by introduction of small lipophilic substituents resulted in improved PK profiles, ultimately leading to compound 13Bh, an extremely potent (K(i)=0.1 nM, EC(50)=4.5 nM) and selective (CC(50) (Huh-7 cells)>50 microM) inhibitor, displaying an excellent PK profile in rats characterized by an oral bioavailability of 54% and a high liver exposure after oral administration.


Subject(s)
Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , Hepacivirus/drug effects , Proline/chemical synthesis , Proline/pharmacology , Serine Proteinase Inhibitors/chemical synthesis , Serine Proteinase Inhibitors/pharmacology , Urea/analogs & derivatives , Urea/chemical synthesis , Urea/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Administration, Oral , Animals , Antiviral Agents/chemistry , Carbamates/pharmacology , Carbamates/therapeutic use , Combinatorial Chemistry Techniques , Drug Design , Male , Models, Molecular , Molecular Structure , Proline/analogs & derivatives , Proline/chemistry , Rats , Rats, Sprague-Dawley , Serine Proteinase Inhibitors/chemistry , Structure-Activity Relationship , Urea/chemistry
8.
Bioorg Med Chem Lett ; 18(18): 5095-100, 2008 Sep 15.
Article in English | MEDLINE | ID: mdl-18722116

ABSTRACT

Starting from the previously reported HCV NS3/4A protease inhibitor BILN 2061, we have used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in which (i) the P3 amino moiety and its capping group have been truncated, (ii) a sulfonamide is introduced in the P1 cyclopropyl amino acid, (iii) the position 8 of the quinoline is substituted with a methyl or halo group, and (iv) the ring size of the macrocycle has been reduced to 14 atoms. SAR analysis performed with a limited set of compounds led to the identification of N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0 [Bartenschlager, R.; Lohmann, V. J. Gen. Virol. 2000, 81, 1631; Vincent Soriano, Antonio Madejon, Eugenia Vispo, Pablo Labarga, Javier Garcia-Samaniego, Luz Martin-Carbonero, Julie Sheldon, Marcelle Bottecchia, Paula Tuma, Pablo Barreiro Expert Opin. Emerg. Drugs, 2008, 13, 1-19]]octadec-7-ene-4-carbonyl}(1-methylcyclopropyl)(1-methylcyclopropyl)sulfonamide 19l an extremely potent (K(i)=0.20 nM, EC(50)=3.7 nM), selective, and orally bioavailable dipeptide NS3/4A protease inhibitor, which has features attractive for further preclinical development.


Subject(s)
Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , Carbamates/pharmacology , Macrocyclic Compounds/pharmacology , Quinolines/pharmacology , Serine Proteinase Inhibitors/chemical synthesis , Serine Proteinase Inhibitors/pharmacology , Sulfonamides/chemical synthesis , Sulfonamides/pharmacology , Thiazoles/chemical synthesis , Thiazoles/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Administration, Oral , Animals , Antiviral Agents/chemistry , Combinatorial Chemistry Techniques , Dogs , Liver/drug effects , Liver/metabolism , Molecular Structure , Rats , Serine Proteinase Inhibitors/chemistry , Structure-Activity Relationship , Sulfonamides/chemistry , Thiazoles/chemistry
9.
Bioorg Med Chem Lett ; 18(17): 4853-8, 2008 Sep 01.
Article in English | MEDLINE | ID: mdl-18678486

ABSTRACT

SAR analysis performed with a limited set of cyclopentane-containing macrocycles led to the identification of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0(4,6)]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide (TMC435350, 32c) as a potent inhibitor of HCV NS3/4A protease (K(i)=0.36nM) and viral replication (replicon EC(50)=7.8nM). TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies. TMC435350 is currently being evaluated in the clinics.


Subject(s)
Carrier Proteins/antagonists & inhibitors , Cyclopentanes/pharmacology , Hepacivirus/drug effects , Hepacivirus/enzymology , Heterocyclic Compounds, 3-Ring/pharmacology , Macrocyclic Compounds/pharmacology , Protease Inhibitors/pharmacology , Sulfonamides/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Viral Proteins/antagonists & inhibitors , Animals , Caco-2 Cells , Cell Line , Cyclopentanes/chemistry , Dogs , Hepatitis C/drug therapy , Heterocyclic Compounds, 3-Ring/chemistry , Humans , Intracellular Signaling Peptides and Proteins , Macrocyclic Compounds/chemistry , Male , Protease Inhibitors/chemistry , Rats , Rats, Sprague-Dawley , Simeprevir , Structure-Activity Relationship , Sulfonamides/chemistry
10.
Eur J Pharm Biopharm ; 70(3): 853-60, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18657611

ABSTRACT

Powders for reconstitution of the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 with low water solubility were developed by using a spray-dry technology. Their flexible dosing ability makes them suitable for patients looking for a different approach for antiretroviral (ARV) therapy. The selection of formulation excipients was based on their potential to create and maintain supersaturation solubility of TMC278 in 0.01 M HCl. Suitable water-soluble carriers for TMC278 were selected by a supersaturation screening to formulate powders for reconstitution by spray-drying. The selected powders for reconstitution were compared to clinical tablets of TMC278.HCl, in vitro using dissolution and stability testing, and in vivo through administration to beagle dogs, fed immediately after dosing. The spray-dried powders for reconstitution made up of TMC278/PVP-VA 64 1:9 (w/w) and TMC278/PVP-VA 64/Cremophor EL 1:8.5:0.5 (w/w/w) showed ease of suspendability, nearly complete dissolution of the drug and acceptable stability after one month storage at 25 and 40 degrees C. In dogs, TMC278 was more slowly absorbed from tablets than from the suspended powders for reconstitution. Compared to the tablet, the relative bioavailability obtained with the powders ranged between 69% and 89% for TMC278/PVP-VA 64 1:9 (w/w) and between 85% and 157% for TMC278/PVP-VA 64/Cremophor EL 1:8.5:0.5 (w/w/w). The absence of differences in vivo and in vitro between the powders made an eventual choice very difficult, yet their advantageous in vivo behaviour and flexible dosing possibility may provide a starting point for paediatric formulations.


Subject(s)
Anti-HIV Agents/chemistry , Excipients/chemistry , HIV Reverse Transcriptase/antagonists & inhibitors , Nitriles/chemistry , Pyrimidines/chemistry , Reverse Transcriptase Inhibitors/chemistry , Administration, Oral , Animals , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacokinetics , Biological Availability , Chemistry, Pharmaceutical , Dogs , Drug Carriers , Drug Stability , Male , Nitriles/administration & dosage , Nitriles/pharmacokinetics , Powders , Pyrimidines/administration & dosage , Pyrimidines/pharmacokinetics , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/pharmacokinetics , Rilpivirine , Solubility , Tablets , Technology, Pharmaceutical/methods
11.
Int J Pharm ; 355(1-2): 38-44, 2008 May 01.
Article in English | MEDLINE | ID: mdl-18337029

ABSTRACT

Factors such as insufficient drug potency, non-compliance and restricted tissue penetration contribute to incomplete suppression of Human Immunodeficiency Virus (HIV) and the difficulty to control this infection. Infusion via standard catheters can be a source of infection, which is potentially life threatening in these patients. We developed an implantable infusion pump, allowing to accommodate large volumes (16-50mL) of high viscous solutions (up to 23.96mPas at 39 degrees C) of anti-HIV agents and providing sustained release of medication: a standard Codman 3000 pump, which was initially developed to release aqueous solutions ( approximately 0.7mPas) into the spinal cord such as for pain medication, was transformed for release of viscous solutions up to 40mPas by adapting the diameter of the capillary flow restrictor, the capillary length and way of catheterisation--by placing the indwelling catheter in the vena cava. A pilot study of the pump implanted in 2 dogs showed continuous steady-state release of the protease inhibitor darunavir (25mg/dog/day administered for 25 days), thereby achieving plasma concentration levels of approximately 40ng/mL. Steady-state plasma levels were reproducible after monthly refill of the pumps. In conclusion, the implantable adapted Codman 3000 constant-flow infusion pump customized to anti-HIV therapy allows sustained release of anti-HIV medication and may represent an opportunity to reduce the pill burden and complexity of dosing schemes associated with common anti-HIV therapy.


Subject(s)
Anti-HIV Agents/administration & dosage , Infusion Pumps, Implantable , Algorithms , Animals , Anti-HIV Agents/blood , Chromatography, High Pressure Liquid , Darunavir , Dogs , HIV Protease Inhibitors/administration & dosage , HIV Protease Inhibitors/blood , Pharmaceutical Solutions , Pilot Projects , Reproducibility of Results , Spectrophotometry, Ultraviolet , Sulfonamides/administration & dosage , Sulfonamides/blood , Viscosity
12.
J Med Chem ; 51(4): 875-96, 2008 Feb 28.
Article in English | MEDLINE | ID: mdl-18254606

ABSTRACT

A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate.


Subject(s)
Antiviral Agents/chemical synthesis , Benzimidazoles/chemical synthesis , Morpholines/chemical synthesis , Pyridines/chemical synthesis , Respiratory Syncytial Viruses/drug effects , Viral Fusion Proteins/genetics , Virus Internalization/drug effects , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Benzimidazoles/pharmacokinetics , Benzimidazoles/pharmacology , Binding Sites , Drug Resistance, Viral , Male , Models, Molecular , Morpholines/pharmacokinetics , Morpholines/pharmacology , Mutation , Protein Binding , Pyridines/pharmacokinetics , Pyridines/pharmacology , Rats , Rats, Sprague-Dawley , Respiratory Syncytial Viruses/physiology , Sigmodontinae , Structure-Activity Relationship
13.
Int J Pharm ; 355(1-2): 45-52, 2008 May 01.
Article in English | MEDLINE | ID: mdl-18082980

ABSTRACT

A dog model was developed to test the capacity of boosters for antiretroviral medication. Two dogs were implanted with a modified constant-flow Codman 3000 infusion pump, adapted to release viscous solutions of darunavir (TMC114) at a constant rate of 25mg/dog/day in the venous blood stream. Booster candidates were given by oral gavage for at least 4 days up to maximum 7 days in cross-over fashion, separated by a wash-out period of minimum 1 week. The booster candidates were tested at doses of 20 and/or 40mg/kg/day: blood sampling for determination of the boosting effect was performed on the last day of booster administration. The model allowed to (1) compare the boosting ratio of these booster candidates based on the exposure (determination of the area under the curve (AUC) of darunavir in presence versus absence of the booster candidate), (2) detect delay in boosting activity by evaluation of the shift of Cmax of darunavir following booster administration versus the Cmax of the booster candidate) and (3) calculate the intrinsic booster capacity, by correcting for the systemic exposure of booster candidate by normalizing the booster ratio for the booster's AUC. The latter parameter (intrinsic booster capacity) allows to determine the booster's metabolic contribution in inhibiting the metabolism of antiretroviral medication (most likely via inhibition of CYP3A4), minimizing the impact of potential effects of the booster at the level of the gastro-intestinal tract.


Subject(s)
Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacology , Antiretroviral Therapy, Highly Active/instrumentation , Infusion Pumps, Implantable , Animals , Anti-HIV Agents/pharmacokinetics , Antiretroviral Therapy, Highly Active/methods , Darunavir , Data Interpretation, Statistical , Dogs , Drug Resistance, Viral , Drug Synergism , HIV Protease Inhibitors/administration & dosage , HIV Protease Inhibitors/therapeutic use , Male , Ritonavir/administration & dosage , Ritonavir/therapeutic use , Sulfonamides/administration & dosage , Sulfonamides/therapeutic use
14.
J Med Chem ; 50(19): 4572-84, 2007 Sep 20.
Article in English | MEDLINE | ID: mdl-17722899

ABSTRACT

We previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus (Andries, K.; et al. Antiviral Res. 2003, 60, 209-219). A lead compound of the series was selected for preclinical evaluation. This drug candidate, JNJ-2408068 (formerly R170591, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern. We herein describe the optimization program to develop compounds with improved properties in terms of tissue retention. We have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1. We have investigated the replacement or the modification of this group, and we suggest that the pKa of this part of the molecules influences both the antiviral activity and the pharmacokinetic profile. We were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.


Subject(s)
Antiviral Agents/chemical synthesis , Benzimidazoles/chemical synthesis , Piperidines/chemical synthesis , Pyridines/chemical synthesis , Respiratory Syncytial Viruses/drug effects , Viral Fusion Proteins/antagonists & inhibitors , Animals , Antiviral Agents/pharmacokinetics , Antiviral Agents/pharmacology , Benzimidazoles/pharmacokinetics , Benzimidazoles/pharmacology , HeLa Cells , Humans , Kidney/metabolism , Liver/metabolism , Lung/metabolism , Male , Piperidines/pharmacokinetics , Piperidines/pharmacology , Pyridines/pharmacokinetics , Pyridines/pharmacology , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Tissue Distribution
15.
J Virol ; 80(24): 12283-92, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17020946

ABSTRACT

We have discovered a novel class of human immunodeficiency virus (HIV) reverse transcriptase (RT) inhibitors that block the polymerization reaction in a mode distinct from those of the nucleoside or nucleotide RT inhibitors (NRTIs) and nonnucleoside RT inhibitors (NNRTIs). For this class of indolopyridone compounds, steady-state kinetics revealed competitive inhibition with respect to the nucleotide substrate. Despite substantial structural differences with classical chain terminators or natural nucleotides, these data suggest that the nucleotide binding site of HIV RT may accommodate this novel class of RT inhibitors. To test this hypothesis, we have studied the mechanism of action of the prototype compound indolopyridone-1 (INDOPY-1) using a variety of complementary biochemical tools. Time course experiments with heteropolymeric templates showed "hot spots" for inhibition following the incorporation of pyrimidines (T>C). Moreover, binding studies and site-specific footprinting experiments revealed that INDOPY-1 traps the complex in the posttranslocational state, preventing binding and incorporation of the next complementary nucleotide. The novel mode of action translates into a unique resistance profile. While INDOPY-1 susceptibility is unaffected by mutations associated with NNRTI or multidrug NRTI resistance, mutations M184V and Y115F are associated with decreased susceptibility, and mutation K65R confers hypersusceptibility to INDOPY-1. This resistance profile provides additional evidence for active site binding. In conclusion, this class of indolopyridones can occupy the nucleotide binding site of HIV RT by forming a stable ternary complex whose stability is mainly dependent on the nature of the primer 3' end.


Subject(s)
DNA Replication/drug effects , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/enzymology , Indoles/pharmacology , Nitriles/pharmacology , Pyridones/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , DNA Primers , Electrophoretic Mobility Shift Assay , HIV Reverse Transcriptase/genetics , Indoles/chemical synthesis , Indoles/chemistry , Kinetics , Nitriles/chemical synthesis , Nitriles/chemistry , Pyridones/chemical synthesis , Pyridones/chemistry , Sequence Analysis, DNA
16.
Org Lett ; 7(26): 5917-20, 2005 Dec 22.
Article in English | MEDLINE | ID: mdl-16354099

ABSTRACT

[reaction: see text] Two short and efficient synthesis routes have been developed for bis-THF-alcohol 2, a key building block of the investigational HIV protease inhibitor TMC114 (1). Using S-2,3-O-isopropylideneglyceraldehyde (4) as the source of chirality, both routes are based on a diastereoselective Michael addition of nitromethane to give predominantly the syn congeners 6 followed by a Nef oxidation and cyclization to afford lactone acetals 8, which are reduced and cyclized to give 2.


Subject(s)
Furans/chemical synthesis , HIV Protease Inhibitors/chemical synthesis , Sulfonamides/chemical synthesis , Cyclization , Darunavir , Furans/chemistry , Furans/pharmacology , HIV Protease Inhibitors/chemistry , HIV Protease Inhibitors/pharmacology , Molecular Structure , Stereoisomerism , Sulfonamides/chemistry , Sulfonamides/pharmacology
17.
Antimicrob Agents Chemother ; 49(6): 2314-21, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15917527

ABSTRACT

The purpose of this study was to characterize the antiviral activity, cytotoxicity, and mechanism of action of TMC114, a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI). TMC114 exhibited potent anti-HIV activity with a 50% effective concentration (EC50) of 1 to 5 nM and a 90% effective concentration of 2.7 to 13 nM. TMC114 exhibited no cytotoxicity at concentrations up to 100 muM (selectivity index, >20,000). All viruses in a panel of 19 recombinant clinical isolates carrying multiple protease mutations and demonstrating resistance to an average of five other PIs, were susceptible to TMC114, defined as a fold change in EC50 of <4. TMC114 was also effective against the majority of 1,501 PI-resistant recombinant viruses derived from recent clinical samples, with EC50s of <10 nM for 75% of the samples. In sequential passage experiments using HIV-1 LAI, two mutations (R41T and K70E) were selected. One selected virus showed a 10-fold reduction in susceptibility to TMC114, but <10-fold reductions in susceptibility to the current PIs (atazanavir was not assessed), except saquinavir. However, when the selected mutations were introduced into a laboratory strain by site-directed mutagenesis, they had no effect on susceptibility to TMC114 or other PIs. There was no evidence of antagonism between TMC114 and any currently available PIs or reverse transcriptase inhibitors. Combinations with ritonavir, nelfinavir, and amprenavir showed some evidence of synergy. These results suggest that TMC114 is a potential candidate for the treatment of both naive and PI-experienced patients with HIV.


Subject(s)
Drug Resistance, Viral , HIV Protease Inhibitors/pharmacology , HIV-1/drug effects , HIV-2/drug effects , Sulfonamides/pharmacology , Cell Line , Cells, Cultured , Darunavir , Drug Resistance, Viral/genetics , HIV-1/classification , HIV-1/genetics , HIV-1/isolation & purification , HIV-2/classification , HIV-2/genetics , HIV-2/isolation & purification , Humans , Leukocytes, Mononuclear/virology , Microbial Sensitivity Tests , Recombination, Genetic
18.
J Med Chem ; 48(6): 1930-40, 2005 Mar 24.
Article in English | MEDLINE | ID: mdl-15771437

ABSTRACT

Human immunodeficiency virus type-1 integrase is an essential enzyme for effective viral replication and hence a valid target for the design of inhibitors. We report here on the design and synthesis of a novel series of phthalimide analogues as integrase inhibitors. The short synthetic pathway enabled us to synthesize a series of analogues with a defined structure diversity. The presence of a single carbonyl-hydroxy-aromatic nitrogen motif was shown to be essential for the enzymatic activity and this was confirmed by molecular docking studies. The enzymatically most active compound from this series is 7-(3,4-dichlorobenzyl)-5,9-dihydroxypyrrolo[3,4-g]quinoxaline-6,8-dione (15l) with an IC(50) value of 112 nM on the HIV-1 integrase enzyme, while ((7-(4-chlorobenzyl)-5,9-dihydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione (15k)) showed an EC(50) of 270 nM against HIV-1 in a cell-based assay.


Subject(s)
Anti-HIV Agents/chemical synthesis , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase/metabolism , Heterocyclic Compounds, 3-Ring/chemical synthesis , Phthalimides/chemical synthesis , Pyrroles/chemical synthesis , Quinoxalines/chemical synthesis , Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , Binding Sites , Cell Line , HIV Integrase/chemistry , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Heterocyclic Compounds, 3-Ring/chemistry , Heterocyclic Compounds, 3-Ring/pharmacology , Humans , Models, Molecular , Phthalimides/chemistry , Phthalimides/pharmacology , Protein Binding , Pyrroles/chemistry , Pyrroles/pharmacology , Quinoxalines/chemistry , Quinoxalines/pharmacology , Structure-Activity Relationship
19.
J Med Chem ; 48(6): 1965-73, 2005 Mar 24.
Article in English | MEDLINE | ID: mdl-15771440

ABSTRACT

On the basis of structural data gathered during our ongoing HIV-1 protease inhibitors program, from which our clinical candidate TMC114 9 was selected, we have discovered new series of fused heteroaromatic sulfonamides. The further extension into the P2' region was aimed at identifying new classes of compounds with an improved broad spectrum activity and acceptable pharmacokinetic properties. Several of these compounds display an exceptional broad spectrum activity against a panel of highly cross-resistant mutants. Certain members of these series exhibit favorable pharmacokinetic profiles in rat and dog. Crystal structures and molecular modeling were used to rationalize the broad spectrum profile resulting from the extension into the P2' pocket of the HIV-1 protease.


Subject(s)
Benzoxazoles/chemical synthesis , Drug Resistance, Multiple, Viral , HIV Protease Inhibitors/chemical synthesis , HIV-1/drug effects , Sulfonamides/chemical synthesis , Thiazoles/chemical synthesis , Animals , Benzoxazoles/chemistry , Benzoxazoles/pharmacology , Binding Sites , Calorimetry , Cell Line , Crystallography, X-Ray , Dogs , Drug Stability , HIV Protease Inhibitors/chemistry , HIV Protease Inhibitors/pharmacology , Humans , In Vitro Techniques , Microsomes, Liver/metabolism , Models, Molecular , Rats , Rats, Wistar , Sulfonamides/chemistry , Sulfonamides/pharmacology , Thermodynamics , Thiazoles/chemistry , Thiazoles/pharmacology
20.
J Med Chem ; 48(6): 2072-9, 2005 Mar 24.
Article in English | MEDLINE | ID: mdl-15771449

ABSTRACT

This paper reports the synthesis and the antiviral properties of new diarylpyrimidine (DAPY) compounds as nonnucleoside reverse transcriptase inhibitors (NNRTIs). The synthesis program around this new DAPY series was further optimized to produce compounds displaying improved activity against a panel of eight clinically relevant single and double mutant strains of human immunodeficiency virus type 1 (HIV-1).


Subject(s)
Anti-HIV Agents/chemical synthesis , HIV Reverse Transcriptase/metabolism , HIV-1/drug effects , Pyrimidines/chemical synthesis , Reverse Transcriptase Inhibitors/chemical synthesis , Anti-HIV Agents/pharmacology , Anti-HIV Agents/toxicity , Cell Line , Drug Resistance, Viral , HIV Reverse Transcriptase/genetics , HIV-1/genetics , Humans , Mutation , Pyrimidines/pharmacology , Pyrimidines/toxicity , Reverse Transcriptase Inhibitors/pharmacology , Reverse Transcriptase Inhibitors/toxicity , Stereoisomerism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...